Galecto To Test GB1211 Combined with Roche’s Tecentriq In First Line Lung Cancer Setting
Galecto Inc (NASDAQ:GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC:RHHBY) to explore the combination of GB1211 in…
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics
Roche Holding AG (OTC:RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand…
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue.
Roche’s Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
The FDA has greenlit Roche Holdings AG’s (OTC:RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with…
Roche’s Alzheimer’s Candidate Secures FDA Breakthrough Designation
Roche Holdings AG’s (OTC:RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer’s disease. Gantenerumab is designed to neutralize…
Labcorp’s At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings’s (NYSE:LH) combined home collection kit to…
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial
BioNTech SE (NASDAQ:BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2…
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holdings AG (OTC:RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or…
Glaxo – Vir Biotech’s COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19 antibody therapy.
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ:XLRN) were capped with a Bloomberg report asserting that the Company is…